Molecular Therapy of Malignant Tumors: Recent Advances and Future Directions

Over the past few years, molecular therapy for malignant tumors has made significant progress. The antiangiogenic treatment approach has been expanded to include inhibitors of the Mammalian target of rapamycin (mTOR) signaling pathway, providing a new effective alternative. In the treatment of advanced renal cell carcinoma, these substances have become established.

The Role of mTOR Inhibitors in Cancer Treatment

This book provides an in-depth exploration of the molecular foundations and mechanisms of action of mTOR inhibitors. It discusses current study results and sheds light on the challenges of clinical management in the treatment of renal cell carcinoma. The possibilities and challenges of combination therapy, taking into account current treatment guidelines, are extensively presented.

About the Book

Published by UNI-MED Verlag AG, this book is a comprehensive resource for healthcare professionals and researchers interested in the molecular therapy of malignant tumors. With its focus on mTOR inhibitors, this book provides a valuable contribution to the ongoing efforts to improve cancer treatment outcomes.

Key Features:

• Explores the molecular mechanisms of mTOR inhibitors in cancer treatment
• Delves into current study results and clinical management challenges
• Discusses the possibilities and challenges of combination therapy
• Provides a comprehensive resource for healthcare professionals and researchers

Publication Details:

Language: German

Publication Date: December 10, 2010

Publisher: UNI-MED Verlag AG (1st edition)